Gut Bacteria Compound Ergothioneine May Reverse Antipsychotic Brain Damage
A microbiome metabolite depleted by antipsychotics protects synapses and cognition — and supplementing it may reverse the damage.
Summary
Researchers discovered that common antipsychotic drugs like olanzapine, risperidone, and clozapine deplete a gut-bacteria-derived compound called ergothioneine, which normally protects the brain. In mice, chronic antipsychotic use disrupted the gut microbiome, damaged the intestinal barrier, and caused measurable cognitive decline. Multi-omics analysis showed ergothioneine was severely reduced in blood and brain tissue — a finding confirmed in human patients on olanzapine. When ergothioneine was supplemented, cognitive impairment was reversed. The mechanism involves reduced oxidative stress in the hippocampus and inhibition of a damaging enzyme called PTP1B. These findings suggest ergothioneine supplementation could be a practical strategy to protect brain health in the millions of people taking antipsychotic medications long-term.
Detailed Summary
Antipsychotic medications are among the most widely prescribed psychiatric drugs globally, yet chronic use is associated with significant cognitive side effects — a problem that has lacked a clear biological explanation. This study, published in Cell Host & Microbe, identifies a compelling gut-brain mechanism that may underlie this harm.
Researchers treated mice chronically with olanzapine and observed gut microbial dysbiosis, compromised intestinal barrier integrity, and measurable cognitive deficits. Using multi-omics approaches — combining genomic, metabolomic, and proteomic analyses — they identified a dramatic depletion of ergothioneine, a sulfur-containing amino acid produced exclusively by certain bacteria, including Cyanobacteria. Critically, this depletion was validated in the blood of human patients taking olanzapine, and replicated in mice treated with risperidone and clozapine, suggesting a class-wide effect.
Fecal microbiota transplantation from antipsychotic-treated mice transferred cognitive impairment to healthy recipients, confirming the microbiome's causal role. Conversely, ergothioneine supplementation reversed cognitive deficits. Mechanistically, ergothioneine reduced hippocampal oxidative stress and inhibited protein tyrosine phosphatase 1B (PTP1B), a redox-sensitive enzyme that disrupts synaptic signaling when activated. Neuronal-specific deletion of PTP1B in the hippocampus completely abolished antipsychotic-induced synaptic and cognitive deficits, pinpointing this pathway as central.
For clinicians, these findings are immediately relevant: patients on long-term antipsychotics may benefit from ergothioneine monitoring or supplementation. Ergothioneine is found in mushrooms and is available as a supplement, making translation feasible.
Caveats include the predominantly mouse-based mechanistic work, limited human validation (blood levels only, no cognitive outcomes in patients), and the fact that this summary is based on the abstract alone. Larger human trials are needed before clinical recommendations can be made.
Key Findings
- Antipsychotics (olanzapine, risperidone, clozapine) deplete gut-derived ergothioneine in mice and human patients.
- Ergothioneine supplementation reverses antipsychotic-induced cognitive impairment in mice.
- Fecal transplant from antipsychotic-treated mice transfers cognitive deficits to healthy mice.
- Ergothioneine protects the brain by reducing hippocampal oxidative stress and blocking the enzyme PTP1B.
- Deleting neuronal PTP1B completely prevents antipsychotic-induced synaptic and cognitive damage.
Methodology
The study used chronic olanzapine-treated mouse models alongside multi-omics analyses (genomic, metabolomic, proteomic) to identify ergothioneine depletion. Causal mechanisms were tested via fecal microbiota transplantation, ergothioneine supplementation, and hippocampal neuronal-specific PTP1B knockout mice. Human validation was limited to blood ergothioneine levels in olanzapine-treated patients.
Study Limitations
Mechanistic findings are primarily from mouse models; human data is limited to blood ergothioneine levels without cognitive outcome measures. The study did not assess whether ergothioneine supplementation is effective in humans or determine optimal dosing. This summary is based on the abstract only, as the full paper was not accessible.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.